Dare Bioscience’s (DARE) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dare Bioscience (NASDAQ:DARE) in a report published on Tuesday,Benzinga reports. The firm currently has a $12.00 price target on the biotechnology company’s stock.

A number of other analysts have also recently issued reports on DARE. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research report on Wednesday, October 8th. Wall Street Zen raised Dare Bioscience to a “hold” rating in a report on Saturday, August 16th. Finally, Maxim Group raised shares of Dare Bioscience from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Thursday, September 4th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Dare Bioscience presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Dare Bioscience Stock Up 2.6%

DARE stock opened at $1.79 on Tuesday. The stock has a market cap of $25.58 million, a P/E ratio of -0.96 and a beta of 0.77. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.06. Dare Bioscience has a twelve month low of $1.61 and a twelve month high of $9.19. The company’s 50 day moving average is $1.96 and its two-hundred day moving average is $2.29.

Dare Bioscience (NASDAQ:DARE) last posted its earnings results on Thursday, November 13th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The company had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.01 million. Research analysts expect that Dare Bioscience will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dare Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. raised its stake in shares of Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after buying an additional 13,650 shares in the last quarter. Virtu Financial LLC acquired a new position in Dare Bioscience during the third quarter worth $37,000. Finally, AMH Equity Ltd raised its position in Dare Bioscience by 17.8% in the second quarter. AMH Equity Ltd now owns 193,603 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 29,301 shares in the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Dare Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.